- Home
- EFSC vs AUPH Comparison
EFSC vs AUPH Comparison
Compare EFSC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSC
- AUPH
- Stock Information
- Founded
- EFSC 1988
- AUPH 1993
- Country
- EFSC United States
- AUPH Canada
- Employees
- EFSC N/A
- AUPH N/A
- Industry
- EFSC Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- EFSC Finance
- AUPH Health Care
- Exchange
- EFSC Nasdaq
- AUPH Nasdaq
- Market Cap
- EFSC 1.9B
- AUPH 1.6B
- IPO Year
- EFSC 1999
- AUPH 1999
- Fundamental
- Price
- EFSC $55.14
- AUPH $16.44
- Analyst Decision
- EFSC Buy
- AUPH Strong Buy
- Analyst Count
- EFSC 3
- AUPH 3
- Target Price
- EFSC $65.67
- AUPH $17.67
- AVG Volume (30 Days)
- EFSC 141.0K
- AUPH 2.2M
- Earning Date
- EFSC 10-27-2025
- AUPH 11-04-2025
- Dividend Yield
- EFSC 2.31%
- AUPH N/A
- EPS Growth
- EFSC 8.68
- AUPH N/A
- EPS
- EFSC 5.13
- AUPH 0.55
- Revenue
- EFSC $646,694,000.00
- AUPH $265,808,000.00
- Revenue This Year
- EFSC $20.14
- AUPH $17.33
- Revenue Next Year
- EFSC $5.15
- AUPH $14.31
- P/E Ratio
- EFSC $10.79
- AUPH $29.89
- Revenue Growth
- EFSC 9.31
- AUPH 20.62
- 52 Week Low
- EFSC $45.22
- AUPH $6.55
- 52 Week High
- EFSC $62.60
- AUPH $16.47
- Technical
- Relative Strength Index (RSI)
- EFSC 57.07
- AUPH 75.78
- Support Level
- EFSC $51.88
- AUPH $14.94
- Resistance Level
- EFSC $55.56
- AUPH $15.81
- Average True Range (ATR)
- EFSC 1.37
- AUPH 0.61
- MACD
- EFSC 0.43
- AUPH 0.06
- Stochastic Oscillator
- EFSC 91.78
- AUPH 97.97
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.